References
Chen, X., Bäumel, M., Männel, D.N., Howard, O.M. & Oppenheim, J.J. J. Immunol. 179, 154–161 (2007).
Chen, X. et al. J. Immunol. 180, 6467–6471 (2008).
Grinberg-Bleyer, Y. et al. J. Clin. Invest. 120, 4558–4568 (2010).
Valencia, X. et al. Blood 108, 253–261 (2006).
Nagar, M. et al. J. Immunol. 184, 3570–3581 (2010).
Zanin-Zhorov, A. et al. Science 328, 372–376 (2010).
Nie, H. et al. Nat. Med. 19, 322–328 (2013).
Kim, E.Y., Priatel, J.J., Teh, S.J. & Teh, H.S. J. Immunol. 176, 1026–1035 (2006).
Tartaglia, L.A. et al. J. Immunol. 151, 4637–4641 (1993).
Chen, X. et al. J. Immunol. 185, 174–182 (2010).
Chen, X. et al. Eur. J. Immunol. 40, 1099–1106 (2010).
Ehrenstein, M.R. et al. J. Exp. Med. 200, 277–285 (2004).
Nadkarni, S., Mauri, C. & Ehrenstein, M.R. J. Exp. Med. 204, 33–39 (2007).
Acknowledgements
We thank G. Marodon for helpful discussion, M. Cherai for technical support and Y. Lombardi for statistical analyses. This work was supported by the Fondation Bettencourt Schueller and by the Association de la Recherche sur la Sclérose en Plaques.
Author information
Authors and Affiliations
Contributions
B.Z., X.C., J.J.O., M.M. and B.L.S. designed and discussed the initial project; B.Z., X.C., A.B., S.G., D.C., M.M. and B.L.S. performed experiments and analyzed data; G.G. gave conceptual advice; B.Z. and B.L.S. wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Figures and Tables
Supplementary Figures 1–8, Table 1 (PDF 917 kb)
Rights and permissions
About this article
Cite this article
Zaragoza, B., Chen, X., Oppenheim, J. et al. Suppressive activity of human regulatory T cells is maintained in the presence of TNF. Nat Med 22, 16–17 (2016). https://doi.org/10.1038/nm.4019
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4019
- Springer Nature America, Inc.
This article is cited by
-
IL-2 immunotherapy for targeting regulatory T cells in autoimmunity
Genes & Immunity (2023)
-
TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4+Foxp3+ regulatory T cells
Cellular Oncology (2023)
-
TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy
Medical Oncology (2022)
-
TNF in the era of immune checkpoint inhibitors: friend or foe?
Nature Reviews Rheumatology (2021)
-
Interleukin-2 and regulatory T cells in rheumatic diseases
Nature Reviews Rheumatology (2021)